Enzymit Secures $10 Million Series A to Revolutionize Bio-Production

Enzymit, a leading synthetic biology startup, has secured $10 million in Series A funding. The investment round was led by Grove Ventures and Khosla Ventures, with participation from previous backers First Star Ventures and Sapir Venture Partners.

Founded in 2020 by Dr. Gideon Lapidoth and COO Dror Baran, the Israeli-based company, headquartered in Ness Ziona, is advancing the field of bio-production through its innovative cell-free production platform. The platform aims to revolutionize manufacturing by speeding up production processes and lowering costs, using complex computational design and deep learning algorithms to create custom enzymes.

These tailor-made enzymes are designed for cell-free systems, overcoming the limitations of traditional cell-based fermentation methods. By eliminating the need for living cells, Enzymit aims to set a new standard in manufacturing, making bio-production more efficient and scalable.

CEO and co-founder Dr. Gideon Lapidoth highlighted the breakthrough, stating, "For decades, bio-production has been limited by the search for natural enzymes that might fit industrial needs,” said Dr. Gideon Lapidoth, CEO and co-founder of Enzymit. “Our AI-powered platform changes this paradigm by designing entirely new enzymes tailored for specific production challenges. This enables us to create the molecules and materials that were previously unattainable or prohibitively costly to produce."

Source: CTech